**Abstract**

**Background:** Etravirine (ETV) was approved as the second generation drug for use in individuals infected with HIV-1 in 2008 by the U.S. FDA with its unique antiviral activity, high specificity, and low toxicity. However, there are some shortcomings of the existing synthetic routes, such as the long reaction time and poor yield.

**Results:** This article describes our efforts to develop an efficient, practical, microwave-promoted synthetic method for one key intermediate of ETV, which is capable of being operated on a scale-up synthesis level. Through this optimized synthetic procedure, the amination reaction time decreased from 12 h to 15 min and the overall yield improved from 30.4 to 38.5%.

**Conclusion:** Overall, we developed a practical synthesis of ETV via a microwave-promoted method, and the synthetic procedure could be amenable to scale-up, and production costs could be significantly lowered.

**Keywords:** Etravirine, Microwave-promoted, Amination, Synthesis

---

**Background**

HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent a potent and promising antiviral agents that specifically target the HIV-1 reverse transcriptase (RT), the primary target for anti-HIV drugs. The NNRTIs were the major components of highly active antiretroviral therapy (HAART). However, the rapid emergence of drug-resistant HIV-1 strains limited their clinical use [1–4]. Etravirine, 2,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile, a second-generation drug of the diarylpyrimidine-based NNRTIs, was approved in 2008 by the U.S. Federal Drug Administration (FDA) for use in HAART [5]. Etravirine is a well-tolerated NNRTI with higher genetic barrier for resistance and good safety profiles compared to the first-generation NNRTIs [6]. However, there are some shortcomings of the existing synthetic routes, such as the long reaction time and poor yield, which lead to the expensive price of etravirine. Therefore, an efficient synthesis of etravirine holds great potential in both scientifically and socially.

**Medicinal chemistry synthesis of etravirine**

The synthetic routes of etravirine disclosed are outlined in Schemes 1, 2, 3 and 4, which is mainly divided into two methods: (1) Method 1: The halogenated pyridines (2 or...
6) are used as starting materials (Schemes 1, 2) [6, 7]; (2) Method 2: 4-guanidinobenzonitrile (12) is selected as starting material or intermediate (Schemes 3, 4) [8, 9].

In Scheme 1, the starting material 5-bromo-2,4,6-trichloropyrimidine (2) was treated with 4-aminobenzonitrile (3) in refluxing dioxane to give the intermediate 4. Treatment of 4 with 4-hydroxy-3,5-dimethylbenzonitrile in N-methylpyrrolidone afforded the key intermediate 5. Then etravirine was obtained by the ammonification reaction of intermediate 5 with ammonia under the condition of high pressure and high temperature.

In another synthetic route (Scheme 2), the starting material 2,4,6-trichloropyrimidine (6) was treated with 4-hydroxy-3,5-dimethylbenzonitrile (7) under the weakly alkaline condition yield the intermediate 8. Then 8 reacted with 4-aminobenzonitrile (3) provided the intermediate 9 and by-product 10, which was separated from each other by recrystallization. Then etravirine was obtained by the ammonification and bromination of intermediate 9 successively. The yield of the overall route can up to 30.4%.

In Scheme 3, etravirine was obtained with the 4-guanidinobenzonitrile (12) as starting material. Firstly, 12 was cyclized with diethylmalonate in the presence of sodium ethoxide in ethanol to give the intermediate 13, which was subsequently treated with POCl3 to form the corresponding derivative 14. Then the bromination of 14 afforded the intermediate 4, which passed through four successive reactions (nucleophilic substitution with the sodium salt of 7, and ammonification) to give etravirine. In Scheme 4, the synthesis route very similar to that in Scheme 3. The more commercially available 4-aminobenzonitrile (3) was used as starting material in this route. Besides, the sequence of the last three steps in Scheme 4 (nucleophilic substitution, ammonification and bromination) is distinct from those in Scheme 3.

Taken together, in the above synthesis methods of etravirine, problems like the following still exist: (1) The starting materials are difficult to obtain (exemplified by compound 2); (2) In the route employing 4-guanidinobenzonitrile as starting material or intermediate, the overall yield is low; (3) The longer amination reaction time and lower yield of the overall route when halogenated pyridine was used as starting material. Therefore, there have an urgent need to find more efficient and practicable methods in the pharmaceutical industry to synthesize etravirine and its intermediates. Comparative analysis the existing routes described above, the route in Scheme 2 has advantages of the accessibility of raw materials and the simplicity of synthetic steps. Inspired by the route in Scheme 2 and considering its deficiency, we became interested in designing a more efficient synthesis through optimizing the amination method with the aim to increase the overall yield of the route and shorten the longer amination reaction time.
Results and discussions
Since Gedye and Giguere published their first articles about microwave-assisted syntheses in household microwave ovens in 1986 [10, 11], the microwave-assisted synthesis method have attracted an increasing number of chemists’ attention for its high efficiency in chemical process. The method have been used in many fields successfully. Considering the longer amination time of the existing process route, we attempt to apply this efficient method in the amination reaction for the purpose of reducing reaction time and improving the yield.

In the preliminary study, we conducted the reaction in an autoclave as the conventional synthesis [5] (Scheme 5). The amination reaction performed very well as the literature reported and the yield ranged from 82.7 to 83.6%. Then we attempted the reaction in the microreactor. When we conducted our first attempt, dioxane, acetonitrile and tetrahydrofuran was used as solvent. The results were frustrated and there no desired product was obtained. We speculated that the poor solubility of the intermediate 9 in these solvent lead to the failure of the reaction. Then some good dissolving solvent of 9 were chosen, such as dimethylformamide (DMF), dimethylsulfoxide (DMSO) and N-methylpyrrolidone (NMP). The results were depicted in Table 1, the reaction conducted very well in all the three solvent with moderate to good yield compared to our preliminary attempt. The results demonstrated that the reaction have the best yield in N-methylpyrrolidone, so it was selected as solvent for the further optimization of the microwave reaction. Further investigation of the amination reaction mainly focus on the amination temperature and reaction time (Table 2). We can conclude that the yield was improved with the increased reaction time and temperature. But there have decreasing tendency of the yield when the temperature above 130 °C and reaction time more than 15 min. After an orthogonal experiment, the optimized conditions of the amination reaction was determined as follows: in the microwave reactor with N-methylpyrrolidone as solvent and reacted in 130 °C for 15 min. The yield of amination reaction can up to 85.6%, which was higher than that of the conventional synthesis method (83.6%).
Discussion
The first step of the process route is a typical $S_{N}Ar$ (addition–elimination) process (Scheme 6). Treatment of equimolar amounts of 4-hydroxy-3,5-dimethylbenzonitrile (7) with 2,4,6-trichloropyrimidine (6) in the presence of potassium carbonate may afford two mono-substituted products 8 and 17 at the position of C$_4$–Cl and C$_2$–Cl of the starting material 6. But the mono-substituted product 8 were obtained with excellent yields, for the reason that there exist a selectivity between C$_4$–Cl and C$_2$–Cl of compound 6 [12]. On account of the $S_{N}Ar$ (addition–elimination) process is thermodynamical control, so the product depend on the stabilization of the intermediate Meisenheimer complex. Compared to the Meisenheimer intermediate 16 where the ring nitrogen ortho to the tetrahedral carbon, the intermediate 15 with the para-quinoid structure can be better bear the negative charge and more stabilization [12], which gives reasonable account for the single mono-substituted products 8.

Conclusions
Etravirine is an essential medicine for the treatment of HIV, which is still inaccessible to millions of people worldwide. To overcome the disadvantageous issues in the existing synthetic methods of etravirine, an efficient and practical synthetic method was optimized in this article. The synthesis was achieved using a linear approach starting from 2,4,6-trichloropyrimidine through a sequence of nucleophilic substitution, ammonification and bromination (Scheme 7). The microwave-promoted amination is the most critical step of this route, and it shorten the amination reaction time from 12 h to 15 min. Moreover, the overall yield of the synthetic route is improved from 30.4 to 38.5% over 4 linear steps. To the best of our knowledge, this is the highest yield for etravirine that has been reported. Moreover, all the synthetic process does not require purification by column chromatography, and the formation of impurities could be suppressed very well. Accordingly, the synthetic procedure could be amenable to scale-up, and production costs could be significantly lowered through this microwave-promoted method.

Table 2 Optimization of amination reaction conditions

| Temperature/°C | 110 | 120 | 125 | 130 | 135 | 140 |
|---------------|-----|-----|-----|-----|-----|-----|
| Time/min 5    | 32.4| 42.1| 45.3| 43.2| 45.2| 47.6|
| Time/min 10   | 46.7| 64.5| 74.2| 71.2| 76.3| 73.6|
| Time/min 15   | 64.4| 78.3| 82.4| 85.6| 85.3| 85.5|
| Time/min 20   | 74.3| 80.8| 82.6| 85.3| 85.6| 85.1|
| Time/min 25   | 80.4| 81.2| 83.1| 85.7| 83.1| 84.3|
| Time/min 30   | 82.5| 81.4| 82.1| 84.2| 84.2| 84.1|

Scheme 5 Amination reaction of the intermediate 9

Scheme 6 The reaction mechanism of the intermediate 6 and 7
Experimental section

All melting points were determined on a micro melting point apparatus and are uncorrected. $^1$H-NMR spectra were obtained on a Bruker Avance 400 NMR spectrometer in the indicated solvents. Chemical shifts are expressed in δ units and TMS as internal reference. Mass spectra was taken on a LC Autosampler Device: Standard G1313A instrument. TLC was performed on Silica Gel GF254 for TLC (Merck) and spot was visualized by iodine vapours or irradiation with UV light (λ = 254 nm).

The microwave reaction was conducted on a CEM Discover (0–600 W, 2450 MHz) instrument and the conventional high pressure reaction was performed on Parr 4590 instrument. Concentration of the reaction solutions involved the use of rotary evaporator at reduced pressure.

4-[(2,6-Dichloro)-4-pyrimidinyloxy]-3,5-dimethylbenzonitrile (8)

2,4,6-Trichloropyrimidine 6 (110 mmol, 20.0 g), diisopro-pylethylamine (132 mmol, 17.0 g) and 3,5-dimethyl-4-hydroxybenzonitrile 7 (110 mmol, 16.2 g) were dissolved in 1,4-dioxane (100 mL) and the mixed solution was heated at 70 °C for 2 h. After the reaction mixture was brought to 10–15 °C, 200 mL water was poured into the mixture and stirred for another 30 min, filtrated. Then the wet cake was dried at 55–60 °C under vacuum to give the intermediate 8 as white solid with a yield of 92.5%. $^1$H NMR (400 MHz, DMSO-\textit{d}_6, ppm) δ: 7.76 (2H, s, C₃,C₅–Ph–H), 7.64 (1H, s, pyrimidine-H), 2.12 (6H, s, CH₃). ESI–MS: m/z 294.28 (M$^+$+1). C₁₃H₉Cl₂N₃O (293.01), mp: 207–209 °C.

4-[[6-Chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile (11)

A mixture of 9 (5.3 mmol, 2.0 g), 25% aq ammonia (15 mL), and N-methylpyrrolidone (20 mL) was put into a microwave reactor and set the condition for 130 °C, 15 min. In the reaction process, the pressure can up to 135 psi. After the reaction mixture was brought to 5–10 °C, 100 mL water was added to this solution followed stirring another 30 min. The generated solid was filtered, washed with 100 mL of water and dried at 45–50 °C to give the crude intermediate 11 as white solid with a yield of 85.6%. $^1$H NMR (400 MHz, DMSO-\textit{d}_6, ppm) δ: 6.93 (1H, s, pyrimidine-H), 6.93 (1H, s, pyrimidine-H), 7.46 (2H, d, J=$8.0$ Hz, C₂,C₆–Ph–H), 7.34 (2H, d, J=$8.0$ Hz, C₃,C₅–Ph–H), 7.46 (2H, d, J=$8.0$ Hz, C₂,C₆–Ph–H), 6.80 (2H, s, NH₂), 5.47 (1H, s, pyrimidine–H), 2.12 (6H, s, CH₃). ESI–MS: m/z 357.4 (M$^+$+1), 379.5 (M$^+$+23). C$_{20}$H$_{16}$N$_{6}$O (356.14), mp: 283–286 °C.

Etravirine (1)

To a cooled solution of 11 (8.4 mmol, 3.0 g) in DCM (30 mL) at 0–5 °C was added bromine solution (9.4 mmol, 1.5 g in 8 mL of DCM). The reaction was stirred at this temperature for 5 h. Then the mixed solution was diluted
with water (50 mL) and basified with 4 M NaOH solution at pH 9–10. The pH of the reaction was maintained between 8 and 9 over a period of another 1 h by adding 4 M NaOH solution and sodium metabisulphite solution. Then the obtained solid was filtered, washed with water (30 mL), and dried at 55–60 °C temperature under vacuum to get crude product, which was following dissolved in methanol (40 mL) at 55–60 °C and treated with activated charcoal. After charcoal clarification, methanol was distilled out, and the residue was recrystallized in ethyl acetate. The crystal was filtered and dried at 55–60 °C under vacuum to give etravirine with a yield of 80.2%. 1H NMR (400 MHz, DMSO-d6, ppm) δ: 9.60 (1H, s, NH), 7.75 (2H, s, C3,C5-Ph-H), 7.54 (2H, d, J=8.0 Hz, C3,C5– Ph-H), 7.43 (2H, d, J=8.0 Hz, C2,C6–Ph–H), 7.13 (2H, s, NH2), 2.12 (6H, s, CH3). ESI–MS: m/z: 435.4 (M+H)+, 427.4 (M+H+23). C20 H15 BrN6 O (434.05), mp: 254–256 °C.

Authors’ contributions
DF, Conceived project, Design of experiments, Data acquisition and analysis, Writing—original draft, Writing—review and editing, FW, Compounds synthesis; ZK, Structure confirmation; DK, Conceived project, Data acquisition and analysis, Writing—review and editing; PZ, Supervision of experiments, Supervision, Writing—review and editing; XL, Conceived project, Supervision, Funding acquisition, Writing—review and editing. All authors read and approved the final manuscript.

Acknowledgements
We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC Nos. 81420108027, 81573347), Young Scholars Program of Shandong University (YSPSDU No. 2016WLJH32), the Fundamental Research Funds of Shandong University (No. 2017JC006), and Key research and development project of Shandong Province (No. 2017CXGC1401).

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data are fully available without restriction.

Consent for publication
The authors declare that the copyright belongs to the journal.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 October 2018 Accepted: 27 November 2018 Published online: 20 December 2018

References
1. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X (2013) HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 33(Suppl 1):E1–E72
2. Zhan P, Pannecoque C, De Clercq E, Liu X (2016) Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem 59:2849–2878
3. Shattock RJ, Warren M, McCormack S, Hankins CAAIDS (2011) Turning the tide against HIV. Science 333:42–43
4. Zuo X, Huo Z, Kang D, Wu G, Zhou Z, Liu X, Zhan P (2018) Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017). Expert Opin Ther Pat 28:299–316
5. Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecoque C, Zhan P, Liu X (2017) Structure-based optimization of thiophen[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants. J Med Chem 60:4424–4443
6. De Corte B, De Jonge MR, Heeres J, Ho CY, Janssen PA, Kavash RW, Koy- mans LM, Kukla MJ, Ludovici DW, Van Aken KJ,Andries KJ. Preparation of arylaminoypyrimidines as inhibitors of HIV replication. WO 2000027825
7. Shashikant J, Golak CM, Shyam T, Ashok C, Mukund KG (2010) An improved synthesis of etravirine. Org Process Res Dev 14:657–660
8. Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA (2011) Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 21:2235–2239
9. Reddy BP, Reddy KR, Reddy DM, Reddy RR, Krishna BV, Reddy AV. Preparation of an etravirine intermediate and polymorphs of etravirine. WO 2012001695
10. Richard G, Frank S, Kenneth W, Humera A, Lorraine B, Lena L, John R (1986) The use of microwave ovens for rapid organic synthesis. Tetrahedron Lett 27:279–282
11. Raymond JG, Terry LB, Scott MD (1986) Application of commercial microwave ovens to organic synthesis. Tetrahedron Lett 27:4945–4948
12. Thorns JD, Nagarajan A (1998) 2,4,6-Trichloropyrimidine. Reaction with 4-substituted phenolate ions. J Heterocyclic Chem. 35:269–273

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions